Ernexa Therapeutics (ERNAW) Return on Equity (2011 - 2026)

Ernexa Therapeutics has reported Return on Equity for 16 years, with the latest figure at 0.02% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 3.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 3.0% YoY), and the FY2025 full-year result was 0.07%, down 7.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.02%, up from 0.05% in the prior quarter.
• The five-year high for Return on Equity was 0.39% in Q1 2024, with the low at 0.07% in Q4 2023.
• Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.0% in 2024.
• Annual changes were most pronounced in 2024 — Return on Equity jumped 41 bps — and 2025, when it plunged 38 bps.
• Ernexa Therapeutics' Return on Equity stood at 0.02% in 2022, then sank by 219 bps to 0.07% in 2023, then jumped by 100 bps to 0.0% in 2024, then sank by 608145 bps to 0.05% in 2025, then soared by 48 bps to 0.02% in 2026.
• The last three Return on Equity figures came in at 0.02% (Q1 2026), 0.05% (Q4 2025), and 0.07% (Q3 2025), per Business Quant data.